ICIs, such as programmed death-1 and programmed death-ligand 1 (PD-L1) inhibitors, function by blocking immune checkpoint pathways that typically downregulate immune responses, thereby reactivating T cells against tumor cells.[4,5] However, despite the advancements in immunotherapy, the response to ICIs in AGC is variable, necessitating the identification of reliable biomarkers that can predict therapeutic outcomes and guide treatment decisions effectively. The gene discussed is CD274; the disease is neoplasm.